Ruxolitinib (S) Size:Solid 2 mg 2 µM）and human primary islets

2 µM）and human primary islets (EC50 ~0

InChi: InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5

InChi: InChI=1S/C27H36N2O5

under the trade names Kaletra and Aluvia

Ruxolitinib (S) Size:Solid 2 mg 2 µM）and human primary isletsS Ruxolitinib is a less active enantiomer of Ruxolitinib, a JAK1 2 inhibitor. S Ruxolitinib was initially developed to target the constitutive activation of the JAK STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti JAK activity by competitive